Last reviewed · How we verify

NCT04144296

Mathematical Arterialisation of Capillary Blood for Blood Gas Analysis in Critical Ill Patients

Status unknown NA Last updated 21 September 2021
What this trial tests

NA trial testing Study procedure in Lung Diseases in 70 participants. Status unknown.

Timeline
1 October 2019
Primary endpoint
1 October 2021
1 November 2021

Quick facts

Lead sponsorRWTH Aachen University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment70
Start date1 October 2019
Primary completion1 October 2021
Estimated completion1 November 2021
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

RWTH Aachen University

Who can join

Adults 18 to 100, any sex, with Lung Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare capillary blood gas analysis compensated by v-TAC software (aCBGE, aCBGF) to arterial blood gas analysis (ABG) in terms of pH, pCO2 and pO2 and the clinical usefulness of this method compared to the gold standard of ABG.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Study procedure

Trials testing the same drug.

Other recruiting trials for Lung Diseases

Currently open trials in the same condition.

Other RWTH Aachen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing